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Low Flow Low Gradient Severe 
Aortic Stenosis: Diagnosis and 
Treatment
Faeez Mohamad Ali, Vindhya Wilson and Rajesh Nair
Abstract
Approximately 40% of patients with aortic stenosis (AS) show discordant 
Doppler-echocardiographic parameters with aortic valve area (AVA) <1 cm2 and/or 
index iAVA <0.6 cm2/m2 (consistent with severe AS) and the mean gradient (MG) 
<40 mmHg, consistent with mild/moderate AS. Accurate diagnosis of true severe low 
flow low gradient AS versus pseudo-severe aortic stenosis is important for prognosis 
and optimal timing for intervention. Doppler echocardiography using intravenous 
low dose dobutamine challenge is widely used for differentiating pseudo-severe 
from true severe aortic stenosis. However, relying on echocardiography alone may 
have limitations in accurate diagnosis. Reliable diagnosis using echocardiography 
is dependent on multiple factors like the angle of interrogation of the aortic jet, the 
assumption that the LVOT area is circular in cross section, optimal echo windows, 
the presence of underlying subclinical coronary artery disease prior to dobutamine 
challenge etc. In this chapter, we describe non-invasive and invasive strategies to 
assess the aortic valve using dobutamine stress. Direct measurement of gradients 
across the aortic valve while estimating the change in cardiac output and aortic valve 
area with increments of dobutamine infusion dose is complementary, safe and useful 
when conventional echocardiography techniques are inconclusive. Finally, the chap-
ter describes effective strategies of treatment for low gradient severe aortic stenosis, 
including the role for diagnostic balloon valvuloplasty, in the era of transcatheter 
valve replacement (TAVR).
Keywords: balloon aortic valvuloplasty, dobutamine stress test, low flow low 
gradient severe aortic stenosis, pseudo-severe aortic stenosis, trans-catheter aortic 
valve replacement
1. Introduction
Degenerative calcific aortic stenosis (AS) is the commonest primary valvular 
heart disease responsible for approximately 85,000 valve replacement procedures 
and 15,000 deaths per year in North America [1].
The diagnosis and staging of AS is primarily based on symptoms and Doppler 
echocardiography. AS is considered severe when the patient has a mean transval-
vular gradient >40 mmHg, a peak aortic jet velocity >4 m/s, an aortic valve area 
(AVA) <1.0 cm2, indexed aortic valve area (iAVA) <0.6 cm2/m2 and a dimensionless 
velocity index <0.25 [2–4].
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However, in up to 40% of patients with AS, there is discordance between aortic 
valve area (<1 cm2 suggesting severe AS) and transvalvular gradients (<40 mmHg 
suggesting non-severe AS) on Doppler echocardiography [5–7]. These patients are 
referred to as having “low gradient” severe AS. Most of these patients have a “low 
flow state” across the aortic valve, which is defined as an indexed stroke volume 
<35 ml/m2. Many of these patients may be quite advanced in the natural history 
of severe AS. Despite challenges in establishing accurate diagnosis, “low gradient” 
severe AS patients tend to have poorer outcomes compared to patients with “high 
gradient” severe AS. This chapter describes the etiology, classification, diagnosis 
and management options of low flow low gradient (LFLG) severe AS.
2. Classification of aortic stenosis
All major guidelines have classified aortic stenosis based on hemodynamic 
parameters, symptoms and the left ventricular (LV) systolic function (Figure 1). 
According to the American College of Cardiology/American Heart Association, 
severe aortic stenosis is classified into asymptomatic severe AS (stage C) and 
symptomatic severe AS (stage D). Asymptomatic severe AS depending on LV 
function is further sub classified into stage C1—with normal LV function and stage 
C2—with reduced LV function (left ventricular ejection fraction (LVEF) <50%). 
Symptomatic severe AS is sub classified into three stages depending on blood flow 
across the aortic valve and hemodynamic characteristics (Figure 2). Normal flow 
(>35 ml/m2), high gradient (>40 mmHg), severe AS (AVA <1 cm2/iAVA <0.6 cm/m2) 
is the most easily recognized entity with little diagnostic confusion (stage D1).
Low flow low gradient (LFLG) severe aortic stenosis (stages D2 and D3) rep-
resents an advanced stage in the hemodynamic spectrum of severe AS with poor 
prognosis and higher surgical morbidity and mortality than normal flow high 
gradient severe AS [8–12].
Although not incorporated into guidelines some authors recognize another 
variant called normal flow low gradient severe AS. This is a relatively poorly 
defined entity with unclear pathophysiology. Apart from measurement errors, one 
proposed explanation is that these patients have reduced arterial compliance (stiff 
arteries), which leads to a faster arterial wave reflection from the periphery. The 
Figure 1. 
Stage of aortic stenosis—adapted and modified from Nishimura et al. [2].
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early reflection of the arterial wave at the end of systole may dampen the transval-
vular gradients, independent of transvalvular flow. This phenomenon may, in part, 
explain the small AVA and low gradient discordance observed in patients with 
normal flow, low gradient severe AS.
2.1 Low flow low gradient severe AS with reduced ejection fraction (stage D2)
This entity is found in about 5–10% of patients with severe AS. It is more 
prevalent in men, and is very often associated with coronary artery disease [13]. 
LFLG severe AS is defined as indexed stroke volume <35 ml/m2, LVEF <50%, AVA 
<1.0 cm2/iAVA <0.6 cm2/m2 and mean aortic valve gradient <40 mmHg [2]. As 
severe AS progresses over several years, the left ventricle responds to the increase in 
afterload by concentric left ventricular hypertrophy. This compensatory mechanism 
helps the left ventricle pump against an increase in afterload as well as offset the 
increase in wall tension. The compensatory mechanism is reflected in the natural 
history of aortic stenosis where patients with severe AS who are truly asymptomatic 
have a relatively long symptom free period. However onset of symptoms indicates 
a significant turning point in the natural history with poor prognosis when left 
untreated (Figure 3). The average life expectancy for patients with severe AS is 
2 years for those with shortness of breath, 3 years for patients with syncope, and 
5 years for those with angina [16].
Patients who start out as normal flow high gradient severe AS eventually transform 
into LFLG severe AS with reduced LVEF through a number mechanisms (Figure 4).  
The long standing persistent left ventricular hypertrophy leads to oxygen supply 
demand mismatch, reduced capillary density, chronic subendocardial ischemia 
and interstitial fibrosis. Another important reason for LV dysfunction is coexistent 
coronary artery disease seen in a majority of these patients—49–76% [8, 9, 12].
Eventually the left ventricle fails to keep up with the high pressure gradients and 
decompensates due to the afterload mismatch. The LV dilates, stroke volumes drops 
Figure 2. 
Subtypes of low-gradient aortic stenosis. AS, aortic stenosis; AVA, aortic valve area; LVEF, left ventricular 
ejection fraction; MG, mean transvalvular gradient; SVi, stroke volume index. Reproduced with permission 
from Clavel et al. [32].
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Figure 3. 
(A) Natural history as reflected by event-free survival in asymptomatic patients with AS. Initial aortic jet 
velocity (Vmax) stratifies patients according to the likelihood that symptoms requiring valve replacement will 
develop over time [14]. (B) Outcomes with very severe AS. Kaplan-Meier event-free survival rate for patients 
with a peak aortic jet velocity of 4.0 m/s or greater [15]. In both A and B, most “events” consisted of the onset of 
symptoms warranting aortic valve replacement.
Figure 4. 
Factors leading to transformation of high gradient severe aortic stenosis to low flow low gradient severe aortic 
stenosis with reduced ejection fraction.
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and LVEF falls. As the flow across the stenosed aortic valve declines, the ability of 
the valve to open (which is flow dependent) reduces and hence the calculated aortic 
valve area is low. The pressure gradients across the valve are measured by modified 
Bernoulli’s equation (P = 4V2, P, transaortic valve pressure gradient; V, maximum 
velocity of the aortic jet). Since flow velocities decline along with the stroke volume, 
the measured pressure gradients also drop exponentially. This leads to LFLG severe 
AS, with overall poor prognosis and a consensus class IIa recommendation for aortic 
valve replacement (AVR).
2.2 Low flow low gradient severe AS with preserved left ventricular ejection 
fraction (stage D3)
As opposed to patients with “classic” LFLG AS with reduced LVEF, those with 
“paradoxical” LFLG AS have preserved LVEF. This entity is defined as an LVEF >50%, 
the presence of a low flow (stroke volume index <35 ml/m2), an AVA <1.0 cm2,  
an iAVA <0.6 cm2/m2, and a mean aortic valve gradient <40 mmHg [2, 5, 17].  
LFLG pattern is seen in 5–15% of patients with severe AS and is more prevalent 
in women and elderly patients. These patients have excessive LV hypertrophy in 
response to the hemodynamic stress. As a result they have small LV cavities and 
hence a low stroke volumes despite the preserved LVEF. Other factors (Figure 5) that 
contribute to low forward flow across the aortic valve include mitral regurgitation/
stenosis, tricuspid regurgitation/stenosis, atrial fibrillation and infiltrative cardio-
myopathies like amyloidosis. Paradoxical LFLG AS shares clinical, pathological and 
hemodynamic similarities with heart failure with preserved ejection fraction. Both 
conditions are characterized by significant concentric left ventricular hypertrophy 
Figure 5. 
Factors leading to transformation of high gradient severe aortic stenosis to paradoxical low flow low gradient 
severe aortic stenosis.
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leading to small cavity size and restrictive physiology. In addition there is marked 
reduction in intrinsic LV systolic function that may not be apparent by routinely 
used echocardiographic indices. Global longitudinal strain is a more sensitive param-
eter that helps unmask the apparently normal LVEF in these patients. It is reduced to 
a larger extent due to fibrosis along the subendocardial layer. These findings suggest 
that paradoxical LFLG AS is a more advanced stage in the hemodynamic spectrum of 
severe AS [5, 18, 19] and classified in guidelines as stage D3.
2.3  Moderate aortic stenosis with left ventricular dysfunction—“pseudo-
severe” aortic stenosis
One of the main challenges in the diagnosis of LFLG severe AS is distinguishing it 
from pseudo-severe AS, i.e., moderate AS with underlying LV dysfunction, unrelated 
to aortic stenosis. In this case, the primary culprit is LV dysfunction; typically due to 
associated cardiomyopathy (ischemic or idiopathic) or myocarditis. The myopathic 
ventricle fails to generate adequate blood flow to open the aortic valve sufficiently, 
hence overestimating severity of AS on echocardiography. At the same time, the gradi-
ents across the aortic valve are low related to lower transvalvular flow. This produces a 
hemodynamic picture similar to LFLG severe AS. Studies have shown that in patients 
with pseudo-severe AS, the 5-year survival with medical therapy is better than in true 
severe AS and comparable with that of propensity matched patients with heart failure 
with reduced ejection fraction and no evidence of valve disease (Figure 6) [20].
Paradoxically, moderate aortic stenosis for a normal ventricle may be function-
ally more significant for the myopathic ventricle. Some studies have suggested that 
moderate AS may have a detrimental effect on outcomes in patients with coexistent 
LV dysfunction. This concept raises the hypothesis that aortic valve replacement 
(AVR) may be beneficial in such patients [21, 22]. Trans-catheter Aortic Valve 
Figure 6. 
Kaplan-Meier survival estimates under conservative treatment among 28 patients with pseudo-severe aortic 
stenosis and 28 propensity-matched patients with systolic heart failure. Reproduced with permission from 
Fougères et al. [20].
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Replacement to UNload the Left ventricle in patients with ADvanced heart failure 
(TAVR UNLOAD) trial is designed to test the above hypothesis. Patients with heart 
failure with reduced ejection fraction and moderate AS confirmed by resting and/
or dobutamine stress echocardiography are randomized to optimized heart failure 
therapy alone versus optimized heart failure therapy plus transcatheter AVR.
3. Diagnosis of low flow low gradient severe aortic stenosis
Transthoracic echocardiogram is the gold standard to detect the “low flow state” 
across the aortic valve. Accurate Doppler echocardiographic measurements of 
stroke volume, AVA, and gradient are important to minimize underestimation of 
severe AS or an overestimation of moderate AS.
3.1 Echocardiographic caveats in estimating AS severity
Typically Doppler echocardiographic assessment is operator dependent. 
Optimal alignment of the continuous wave Doppler beam with the direction of the 
aortic flow jet is crucial to accurately quantify aortic valve gradient, aortic valve 
area and thereby severity of AS. The apical window detects peak velocity in 40% 
of cases where as the right parasternal window picks up peak velocity in 50% of 
cases [23]. A multiwindow approach is recommended which includes apical, right 
parasternal, suprasternal and right supraclavicular windows.
The most common technical pitfall that may lead to an erroneous diagnosis of low-
flow state and overestimation of AS severity is underestimation of the left ventricular 
outflow tract (LVOT) diameter. The effective AVA is determined by the continuity 
equation method (Figure 7), which is based on the principle that the flow across the left 
ventricular outflow tract should be equal to the flow across the aortic valve. Since the 
LVOT diameter is squared in the equation, an underestimation of the LVOT diameter 
may lead to underestimation of valve area and thus the false conclusion that the patient 
has LFLG severe AS when, in fact, the patient has normal flow and/or moderate AS.
The 2009 European Association of Echocardiography/American Society of 
Echocardiography guidelines suggest measuring the diameter and velocity 5–10 mm 
below the aortic annulus. However, recent studies suggest measuring the LVOT 
diameter inner-edge-to-inner-edge from the base of the right coronary cusp ante-
riorly to the commissure posteriorly [24, 25]. From a practical standpoint, an easy 
way to measure the LVOT diameter is to assess the pulse wave Doppler signal from 
the distal to proximal LVOT in the apical view. The LVOT velocity time integral is 
then measured just below the point where aliasing is seen, when the flow signals are 
smooth with sharp borders. The LVOT diameter is ideally measured at this point in 
the parasternal long axis view (Figure 8).
3.1.1 Dobutamine stress echocardiography
Once technical errors in measurement are ruled out, it is essential to distinguish 
LFLG true severe AS from pseudo-severe AS. deFilippi et al. [26] were the first to 
demonstrate that low dose (up to 20 μg/kg/min) dobutamine stress echocardiogra-
phy (DSE) may be used in these patients to distinguish true versus pseudo-severe 
stenosis. The use of DSE for this purpose has received a class IIa (level of evidence: B)  
recommendation in the American College of Cardiology/American Heart 
Association-European Society of Cardiology (ACC/AHA-ESC/EACTS) guidelines 
[1–3], and a similar protocol has also been used for invasive assessment in cardiac 
catheterization laboratory by Nishimura et al. [27].
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Dobutamine recruits myocardial contractility in normal and hibernating 
myocardium, thus enhancing stroke volume and transvalvular flow. This is referred 
to as “stroke volume reserve.” Patients with more than 20% rise in stroke volume at 
peak dobutamine levels are referred to as having stroke volume reserve. When the 
flow across the valve increases, depending on the underlying condition, one of two 
possibilities occurs. If the patient has true severe AS, the valve being intrinsically 
restricted cannot open up further. In this case the transaortic gradients will increase 
with little or no change in aortic valve area. On the other hand in patients with 
pseudo-severe AS, aortic valve area increases significantly (>0.6 cm2/m2) with little 
or no change in trans-aortic gradients (Figure 9).
Though not incorporated into guidelines, in our experience, DSE can also be used 
in patients with LFLG severe AS with preserved LVEF. Dobutamine is able to recruit 
the subendocardial longitudinally oriented myocardial fibers and further increase 
transvalvular flow. Studies have estimated that about 30–40% of patients with LFLG 
severe AS may not have adequate stroke volume reserve (<20% rise in stroke volume 
with peak dobutamine stress) [9, 21, 26–28]. They have higher operative mortality 
(22–33%) than those with flow reserve (5–8%) [9]. However the presence or absence of 
flow reserve cannot be used to predict recovery of LV function after valve replacement 
Figure 7. 
Continuity equation, formula to calculate aortic valve area. The LVOT is assumed to be cross sectional in area.
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and cannot be used to determine long term prognosis. The French Multicenter Study 
of LFLG AS reported that, in patients with no LV flow reserve who survived surgical 
aortic valve replacement (SAVR) had similar improvement in post-operative LVEF and 
late survival rate compared to patients with preserved LV flow reserve [29] (Figure 10).
These findings suggest that DSE is useful to distinguish true severe from pseudo-
severe AS and estimate operative risk. However, DES does not predict recovery of 
Figure 8. 
The pulse wave Doppler is walked from the distal to proximal LVOT. At point 3, aliasing is noted suggesting 
that the Doppler signal is within the turbulent aortic jet. The pulse wave Doppler is moved just distal to point 
3 (at point 2) where laminar LVOT velocities are seen. The LVOT VTI is measured at this point and the LVOT 
diameter at this corresponding point in the parasternal long axis view.
Figure 9. 
In the presence of stroke volume reserve, if the valve area remains more or less constant with increase in 
gradient >40 mmHg, it is suggestive of true severe AS. On the other hand, if the valve area increases with no 
significant change in gradients, it is suggestive of pseudo severe AS.
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LV function, improvement in symptom status, and late survival after SAVR [9, 13, 30].  
Though the absence of flow reserve portends higher perioperative mortality, DSE 
should only be used as a diagnostic modality. The absence of LV flow reserve should 
not exclude patients for AVR [9, 12].
3.1.2 Projected effective orifice area
DSE results maybe inconclusive in 30–40% due to inadequate stroke volume 
reserve [9, 13]. In this patient subset, the investigators of the TOPAS (Truly or 
Pseudo-Severe Aortic Stenosis) study proposed to calculate the projected effective 
orifice area (EOA) that would have occurred at a standardized flow rate of 250 ml/s 
(EOAProj) [21, 31] (Figure 11). This parameter, standardized for flow, has been 
shown to better predict the actual hemodynamic severity of the valve stenosis and 
the clinical outcome of patients with classical or paradoxical LFLG AS, as com-
pared with standard stress echocardiography parameters [8, 21, 33]. A projected 
AVA <1.0 cm2 confirms the presence of true severe AS (Figure 11). Some patients 
may not have an adequate increase in stroke volume but nevertheless will have an 
increase in transvalvular flow rate due to shortening of ejection time. The phase III 
of the TOPAS study is currently underway and is expected to be completed by 2022.
3.1.3 CT calcium score of the aortic valve
About 15–20% of patients may have inconclusive results from DSE and may not 
have adequate transvalvular flow rate to calculate projected effective orifice area. 
DSE can be used in patients with paradoxical LFLG AS; however, some patients with 
very small LV cavities can develop dynamic LVOT obstruction and hypotension. For 
such patients, an alternative method to assess aortic stenosis severity is proposed.
Multi detector computerized tomography (MDCT) scan without contrast can 
accurately quantify calcium distribution along the AV leaflets. Calcium burden 
along the AV leaflets has been shown to correlate with severity of aortic stenosis 
[34]. It is an anatomical test independent of hemodynamics, blood flow and does 
not require administration of contrast or any stress agents. For the quantitation of 
calcification, a non-contrast MDCT scan during trained end-inspiration breath-
hold is performed. Radiation exposure for such an examination is <3 mSV. The 
amount of calcification in the region of the aortic valve is quantitated using the 
Figure 10. 
Patients with no LV flow (contractile) reserve (Group II) defined as 20% increase in stroke volume during DSE 
have markedly reduced survival compared with those with LV flow reserve (Group I), regardless of the type of 
treatment. Aortic valve replacement is associated with dramatic improvement in survival in patients with LV 
flow reserve and a trend for better survival in those with no flow reserve. *p 0.001 versus medical; §p 0.07 versus 
medical. Adapted with permission from Monin et al. [9].
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modified Agatston method, in which calcification is defined as four adjacent pixels 
with a density >130 Hounsfield Units [35]. The aortic valve calcium score measured 
by MDCT strongly correlates with hemodynamic severity, the progression rate, 
and the clinical outcomes of AS patients [34, 36, 37]. Women tend to develop less 
calcification for the same degree of severity of stenosis. Cut off values for valve 
calcification to differentiate severe versus non-severe AS in men is >2000 AU and in 
women >1200 AU [34, 38]. The same approach should be applied when using cutoff 
point for aortic valve calcium density (i.e., calcium score indexed to LVOT area): 
>500 AU/cm2 in men versus >300 AU/cm2 in women [34–38] (Figure 12).
It is important to note that MDCT grossly underestimates valve fibrosis and 
hence significantly underestimates severe AS in younger patients [39]. Hence this 
technique may be used in older patients where the degenerative aortic valve pathol-
ogy is driven by valve calcification.
3.1.4 Invasive assessment of aortic stenosis in the catheterization laboratory
3.1.4.1 Pitfalls of echocardiography in diagnosis of AS
The advent of echocardiography revolutionized the field of cardiology providing 
hemodynamic data that could only be previously obtained by invasive cardiac cathe-
terization. However echocardiographic derivations are based on some basic assump-
tions, which might not be reliable for all patient anatomy. Furthermore, there are 
limitations on subjective assessment by personnel with varying experience. Doppler 
measurements are dependent on the angle of insinuation of the sound waves against 
the jet of blood flow across the aortic valve (Figure 13). Depending on the restric-
tion along the leaflet coaptation edges, the jet of blood through the stenosed AV, can 
be eccentric. This makes it almost impossible to align the continuous wave Doppler 
perpendicular to the jet. The peak velocity is inversely proportional to the cosine 
of the angle of insinuation. Even a 1° off axis tilt may reduce the peak velocity by 
0.04 m/s representing an error of 1%, considering a cut off value of 4 m/s for severe 
aortic stenosis. When the estimated velocity is squared to calculate pressure gradient 
across the aortic valve, any error is exponentially increased.
Figure 11. 
DSE in a patient with low flow low gradient state across the aortic valve. Even with dobutamine the valve area 
is 0.81 cm2 and the mean gradient is still <40 mmHg. Due to inconclusive results, the projected effective orifice 
area is calculated at a normalized flow rate of 250 ml/s which is 0.84 cm2 suggesting the presence of true severe 
AS. Adapted with permission from Clavel et al. [32].
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Another common limitation of echocardiography is the assumption that LVOT is 
circular in cross section, when in fact it is circular in only 1–2% of cases (Figure 14). 
The LVOT is a three-dimensional (3D) dynamic structure that is often elliptical, 
with the antero-posterior dimension representing the smaller minor axis diameter, 
as compared with the generally larger diameter in the sagittal plane. Hence, 2D 
echocardiography may underestimate the LVOT area compared with 3D imaging 
modalities such as 3D echocardiography, MDCT, or cardiac magnetic resonance 
[40–43]. To overcome the potential underestimation of the LVOT diameter and 
stroke volume and AVA by 2D echocardiography, the use of a hybrid approach has 
been suggested, where the LVOT area is measured by MDCT or 3D echocardiog-
raphy and the LVOT and aortic flow velocities are measured by Doppler echocar-
diography [43, 44]. However, it is also important to note, the AVA value generally 
used to define severe AS <1.0 cm2, has been established and validated by outcome 
studies, where AVA was measured by standard 2D Doppler-echocardiography  
[2, 4]. A recent study demonstrated that the hybrid approach systematically overes-
timates the LVOT area and thus AVA. The best discriminative hybrid AVA to predict 
mortality in patients with AS under medical treatment was larger (1.2 cm2) versus 
the Doppler-echocardiographic AVA (1.0 cm2) [43].
Finally, it becomes difficult to obtain LVOT velocity time integral when there 
is associated subaortic fixed or dynamic obstruction contributing to transvalvular 
gradients.
Figure 12. 
Quantitation of aortic valve calcium by multi-detector computed tomography for the assessment of stenosis severity 
in low-gradient aortic stenosis. (A) Multi-detector computed tomography can be used to quantitate aortic valve 
calcification by the modified Agatston method. With this method, calcification is defined as four adjacent pixels 
with density 0.130 Hounsfield units. Different cut-point values of valve calcium score should be used in women 
(0.1200 AU) versus men (0.2000 AU) to differentiate true-severe versus pseudo-severe stenosis in low-flow, low-
gradient aortic stenosis. (B) Serial multi-detector computed tomography slices at the level of the aortic valve showing 
a severely calcified valve with a calcium score of 5040 AU consistent with true-severe aortic stenosis. Calcified areas 
are displayed in yellow in the bottom images. (C) Mild calcification (score 271 AU) consistent with pseudo-severe 
aortic stenosis. (D) Pitfalls in the assessment of aortic valve calcification by multi-detector computed tomography. 
For the calculation of calcium score, it is important to only include aortic valve calcification and exclude calcification 
of aorta, coronary arteries, LVOT, and mitral annulus. Adapted with permission from Clavel et al. [32].
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3.1.4.2 Invasive assessment of severe AS
Currently invasive measurement is recommended only when non-invasive tests 
are inconclusive, the patient has poor echo windows or when there is significant 
discrepancy between the patient’s clinical symptoms and echocardiographic data. 
Figure 15 shows the steps of invasive assessment of aortic stenosis in the catheter-
ization lab. Ideally simultaneous pressure gradients are measured by obtaining dual 
arterial access. Single arterial puncture may also be used for diagnosis by inserting a 
7F long sheath reaching the ascending aorta from where pressure can be transduced 
from the side port of the long sheath. The pressure from the left ventricle should 
be transduced through a 5F pigtail catheter inserted into the left ventricle through 
the long sheath. The cardiac output is measured either by thermodilution using a 
Swan Ganz catheter or by Fick’s principle. Dobutamine stress can be achieved using 
incremental doses, infused through a venous sheath. Cardiac output, mean gradient 
across the aortic valve, aortic valve area and iAVA is calculated after at least  
2 minutes of incremental dobutamine infusion [27].
Figure 13. 
Doppler measurements are angle dependent. For optimal values the angle of insinuation should be parallel/
antiparallel (0 or 180°) to the flow of blood. As the Doppler angle increases, the measured velocities decrease, 
thus underestimating velocities.
Figure 14. 
CT showing elliptical shape of the LVOT.
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Figure 15. 
Invasive assessment of low flow gradient AS in the Cathlab. Panel A shows the initial setup of the catheters. 
A 7F long sheath is positioned with its tip in the ascending aorta from where aortic pressures are transduced. 
A 5F pigtail is positioned in the LV through the long sheath to measure LV pressures. A Swan Ganz catheter is 
positioned in the pulmonary artery to measure cardiac output at each stage. Panel B—at baseline the patient 
is shown to have an indexed valve area of 0.5 cm2, with a mean gradient of 34 mmHg across the aortic valve. 
Panel C—with 10 μg/min of dobutamine, the trans-aortic gradients increase from 34 to 57 mmHg with no 
significant change in indexed valve area suggesting the presence of true severe AS.
Figure 16. 
Four-step algorithm for the diagnostic and therapeutic management of low-gradient AS. AVC ¼ aortic 
valve calcification; AVCd ¼ aortic valve calcification density; AVR ¼ aortic valve replacement; CMR ¼ 
cardiac magnetic resonance; MDCT ¼ multi-detector computed tomography; RCT ¼ randomized controlled 
trial; TEE ¼ transesophageal echocardiography; TTE ¼ transthoracic echocardiography. Reproduced with 
permission from Clavel et al. [1].
15
Low Flow Low Gradient Severe Aortic Stenosis: Diagnosis and Treatment
DOI: http://dx.doi.org/10.5772/intechopen.84435
Invasive assessment is not limited by the factors that confound echocardio-
graphic measurement mentioned above. In the presence of serial obstruction, an 
end hole catheter can be positioned above and below the point of interest and pres-
sure gradients can be reassessed. In this scenario, it is possible to determine the site 
that contributes maximally to gradients—either the valve or the obstruction further 
down in the LVOT, thus facilitating accurate diagnosis.
Another advantage of invasive assessment is that the operators often perform 
coronary angiography prior to potentially inducing dobutamine stress. When there 
is no flow limiting coronary artery disease, higher doses of dobutamine (up to 40 μg/
kg body weight) can be used to obtain a conclusive result. When there is associated 
significant coronary artery disease, high dose dobutamine (>30 μg/kg body weight) 
can result in a “biphasic response,” further reducing blood flow across the aortic 
valve, thus confounding results. This is one of the main reasons why a low dose 
dobutamine is recommended when doing a DSE. In the cardiac catherization labora-
tory however, any significant coronary artery disease can be treated percutaneously 
before escalating to higher doses of dobutamine to diagnose LFLG severe AS.
The disadvantage of invasive assessment is the potential complications of car-
diac catheterization, especially when crossing the heavily calcified aortic valve; in 
particular stroke. In the presence of a small aortic root, the phenomenon of “pres-
sure recovery” may confound gradients by increasing aortic pressure and under 
estimating transvalvular pressure gradients.
The diagnosis of LFLG severe aortic stenosis requires a systematic approach with 
a series of tests. Figure 16 summarizes an algorithm for assessment of low flow low 
gradient aortic stenosis.
4. Prognosis and management
The importance of establishing the diagnosis of LFLG severe AS is reflected in 
its differing prognosis to high gradient severe AS. Not only are the outcomes with 
conservative management worse in LFLG AS, studies have also suggested poorer 
outcomes following intervention.
4.1 “Classical” low flow low gradient severe AS with reduced left  
ventricular ejection fraction: (stage D2)
Among the subgroups of severe AS, classical LFLG AS has the worst clinical 
outcome. With medical management the 2-year survival is approximately 40–60%. 
Thirty-day mortality of SAVR is high depending on the presence or absence of flow 
reserve (8–33%) [8, 9, 12, 13, 29]. However, if patients survive SAVR, there is a 
prognostic benefit compared to medical therapy. There is limited head to head ran-
domized data comparing SAVR and TAVR in patients with LFLG severe AS. There 
are few studies that suggest that TAVR leads to better and faster LV function recov-
ery compared to SAVR [45, 46]. It is well known that TAVR, especially with supra-
annular valves leads to less patient prosthesis mismatch, which is an independent 
predictor of worse outcomes [46], especially in patients with reduced LV ejection 
fraction. In patients with no flow reserve who represent the highest risk subgroup, 
TAVR may have a definite survival benefit over SAVR. Thought the PARTNER I trial 
conclusively proved the superiority of TAVR to medical management and similar 
outcomes to SAVR [47], patients with no LV flow reserve as well as those with very 
low LVEF were excluded. More randomized studies are needed to confirm the 
superiority of TAVR over SAVR in patients with classical LFLG severe AS (stage D2).
The heart team plays the central role in selecting the most appropriate modality  
of treatment, i.e., TAVR versus SAVR versus medical management (Figure 17). 
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A comprehensive risk stratification algorithm that takes into consideration risk 
scores (STS), frailty indices, major organ compromise and procedure specific 
impediments is used by the heart team to risk stratify the patient. Ideally the risk 
stratification process may also take into consideration specific factors that are not 
mentioned in the guidelines. These include preoperative NHYA class >III, low 
trans-aortic gradient (<20 mmHg), absence of flow reserve and reduced global 
longitudinal strain. A reduced global longitudinal strain, by itself suggests high 
risk, independent of risk scores (STS/Euroscore) [8, 9, 12].
Palliative balloon aortic valvuloplasty and medical management should be con-
sidered in patients with an expected life expectancy <1 year (Figure 17). In patients 
with classical LFLG severe AS with prohibitive and high surgical risk TAVR is 
recommended. In patients with intermediate surgical risk, SAVR or TAVR may 
be considered depending heart team evaluation; depending on other factors such 
as frailty, major organ compromise and procedure specific impediments (hostile 
chest in case of SAVR or vascular access route for TAVR).
4.2  Paradoxical low flow low gradient severe AS with preserved ejection 
fraction (stage D3)
Patients with paradoxical LFLG AS fare better than patients with classical LFLG 
AS [5, 18, 48]. The PARTNER I cohort B is the only randomized trial that reports 
better survival after TAVR compared to medical management [47], all other studies 
Figure 17. 
Algorithm for the management of classical (reduced left ventricular ejection fraction) low-flow, low-gradient 
aortic stenosis. AoV, aortic valve; BAV, balloon aortic valvuloplasty; MDCT, multi-detector computed 
tomography; SAVR, surgical aortic valve replacement; TAVR, transcatheter aortic valve replacement. 
Reproduced with permission from Clavel et al. [32].
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being observational. AVR reduces mortality by 57% in patients with paradoxical 
LFLG AS [49].
LVEF is a relatively poor and misleading parameter in assessing LV function 
especially in paradoxical LFLG AS. Higher degree of myocardial fibrosis docu-
mented either by cardiac magnetic resonance imaging or global longitudinal strain 
are independent risk factors for mortality in patients with paradoxical LFLG AS 
[50, 51].
The role of plasma brain natriuretic peptide (BNP) in risk stratification of 
patients with paradoxical LFLG AS is unclear [30]. Owing to significant LV con-
centric remodeling and small LV cavities, the LV wall stress may even be normal, 
thus the extent of myocardial stretch and release of BNP may not accurately 
reflect the severity of impairment of myocardial structure/function in these 
patients.
A systematic heart team approach is recommended to optimize outcomes 
(Figure 18). Aortic valve replacement should be considered in symptomatic 
patients with paradoxical LFLG and true severe AS. TAVR may be superior to SAVR 
in patients with paradoxical LFLG AS [47]. Certain factors intrinsic to patients with 
paradoxical LFLG AS pose higher surgical risks compared to patients with high 
gradient AS. These include higher prevalence in female sex, older age, systemic 
hypertension, atrial fibrillation, restrictive LV physiology and smaller aortic annu-
lus that predisposes to patient prosthesis mismatch [52–54]. TAVR was associated 
Figure 18. 
Algorithm for the management of paradoxical (preserved left ventricular ejection fraction) low-flow, low-
gradient aortic stenosis. AVAi, indexed aortic valve area; MR, mitral regurgitation; MS, mitral stenosis; TR, 
tricuspid regurgitation. Reproduced with permission from Clavel et al. [32].
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with better 1-year survival compared with SAVR in patients with paradoxical LFLG 
AS in the PARTNER-I Cohort A trial. Further studies are needed to confirm the 
potential superiority of TAVR versus SAVR in this subset of patients.
5. Role of diagnostic balloon aortic valvuloplasty
In 1986, Cribier et al. [55] first described balloon aortic valvuloplasty (BAV) 
as a treatment strategy for patients with symptomatic severe AS presenting in 
cardiogenic shock, or who were deemed too high risk for conventional SAVR. Due 
to procedural complications, high incidence of restenosis within 6 months, lack of 
sustained clinical and hemodynamic benefit, BAV was not routinely performed. 
Furthermore, mortality rates within a year of BAV was similar to others with severe 
AS who were managed conservatively [56].
Table 1 lists the current status of BAV according to major guidelines. BAV has 
a class IIb recommendation for use as a bridge therapy to TAVR or SAVR in hemo-
dynamically unstable patients at high risk for surgery. In the European guidelines 
(2017) BAV is recommended as a palliative measure in patients not suitable for 
TAVR or SAVR and in patients with symptomatic severe AS who require urgent 
noncardiac surgery. The American Heart Association (AHA)/American College 
of Cardiology (ACC) guidelines (2014) are similar to the European guidelines 
except they do not recommend the use of BAV as a palliative procedure nor its use 
in patients undergoing urgent non-cardiac surgery. However it does acknowledge 
that some patients report an improvement in their symptoms post BAV. The role of 
BAV as bridge to decision in high-risk patients has been supported by a number of 
studies [57]. The rationale behind such a strategy is listed below.
i. BAV helps to choose the best therapeutic option for each patient; avoiding 
expensive or high risk intervention for patients who may not have prognostic 
benefit from definitive treatment of AS.
ii. BAV may be utilized to palliate symptoms and reduce operative risk while 
awaiting TAVR or SAVR.
iii. BAV may be used as a diagnostic procedure especially in patients with 
concomitant severe pulmonary disease. The improvement in symptom status 
post BAV can attribute dyspnea to severe AS rather than lung disease alone.
iv. DSE is used to assess contractile reserve in patients with severe AS. It helps in 
diagnosis and predicting perioperative mortality but cannot predict LV func-
tion recovery. In this subgroup of patients, LV function can be reassessed 
after 4–8 weeks after “diagnostic” BAV. Recovery of LV function post BAV 
is a good indicator of contractile reserve and predicts sustained LV function 
improvement post SAVR/TAVR [58].
v. It has been demonstrated that nearly 50% of patients with severe AS and 
coexistent mitral regurgitation (MR) showed a reduction in the magnitude 
of MR after BAV [59]. A similar reduction is also seen with pulmonary artery 
systolic pressure [60]. BAV therefore negates the need for multiple valve 
intervention and reduces the overall the risk of SAVR.
vi. BAV may be used as a palliative procedure in patients with serious comor-
bidities, frailty, cognitive alteration, severe lung disease or life expectancy 
less than a year.
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6. Conclusion
Clinicians should be mindful that patients with symptomatic severe AS may 
well have low flow and thereby low gradient. Occasionally symptoms may represent 
severity of underlying heart failure rather than the severity of AS. Established mini-
mally invasive trans-catheter therapies, although has improved associated morbidi-
ties of SAVR for intermediate and high-risk patients, it is important that treatment 
is directed to those who will benefit the most. Accurate diagnosis of severe AS is 
important as treatment modalities and its timing can offer prognostic benefits in 
the immediate and long term.
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